

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Brooks Michael J <hr/> (Last) (First) (Middle) C/O EDESA BIOTECH INC. 100 SPY COURT <hr/> (Street) MARKHAM A6 L3R 5H6 <hr/> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol Edesa Biotech, Inc. [EDSA]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President		
			3. Date of Earliest Transaction (Month/Day/Year) 06/07/2019					
			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$0.38 ⁽¹⁾	06/07/2019		A		128,753 ⁽²⁾⁽³⁾		(4)	08/28/2027	Common Shares	128,753	\$0	128,753	D	
Stock Option (right to buy)	\$0.38 ⁽¹⁾	06/07/2019		A		22,934 ⁽²⁾⁽³⁾		(5)	09/26/2027	Common Shares	22,934	\$0	22,934	D	
Stock Option (right to buy)	\$0.38 ⁽¹⁾	06/07/2019		A		1,529 ⁽²⁾⁽³⁾		(6)	12/28/2028	Common Shares	1,529	\$0	1,529	D	

Explanation of Responses:

- In Canadian currency.
- On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa.
- All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019.
- This option was fully vested on 8/28/17.
- This option vests and becomes exercisable 1/3 on 9/26/18, and monthly thereafter through 9/26/20.
- This option vests and becomes exercisable 1/3 on 12/28/19, and monthly thereafter through 12/28/21.

/s/Michael S. Brooks

06/11/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.